Current Report Filing (8-k)
April 19 2017 - 9:23AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
The
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): April 18, 2017
CORBUS
PHARMACEUTICALS HOLDINGS, INC.
|
(Exact
name of registrant as specified in its charter)
|
Delaware
|
|
000-55327
|
|
46-4348039
|
(State
or other jurisdiction
|
|
(Commission
|
|
(IRS
Employer
|
of
incorporation)
|
|
File
Number)
|
|
Identification
No.)
|
100
River Ridge Drive, Norwood, MA
|
|
02062
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code:
(617) 963-0100
Not
Applicable
|
(Former
name or former address, if changed since last report.)
|
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item
7.01. Regulation FD Disclosure.
On
April 18, 2017, Corbus Pharmaceuticals Holdings, Inc. (the “Company”) used the slides attached hereto as Exhibit 99.1
in connection with management presentations to describe its business.
The
information in this Current Report on Form 8-K under Item 7.01, including the information contained in Exhibit 99.1, is being
furnished to the Securities and Exchange Commission, and shall not be deemed to be “filed” for the purposes of Section
18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section, and shall not be deemed to
be incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, except as
shall be expressly set forth by a specific reference in such filing.
Item
9.01. Financial Statements and Exhibits.
(d)
The following exhibit is furnished with this report:
Exhibit
No.
|
|
Description
|
|
|
|
99.1
|
|
Investor
Presentation.
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
CORBUS
PHARMACEUTICALS HOLDINGS, INC.
|
|
|
|
Dated:
April 18, 2017
|
By:
|
/s/
Yuval Cohen
|
|
Name:
|
Yuval
Cohen
|
|
Title:
|
Chief
Executive Officer
|
EXHIBIT
INDEX
Exhibit
No.
|
|
Description
|
|
|
|
99.1
|
|
Investor
Presentation.
|
Corbus Pharmaceuticals (NASDAQ:CRBP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Corbus Pharmaceuticals (NASDAQ:CRBP)
Historical Stock Chart
From Sep 2023 to Sep 2024